目的 探究采用注射用益氣復(fù)脈（凍干）聯(lián)合替格瑞洛治療冠心病心絞痛的臨床效果與安全性。方法 選取商丘市第一人民醫(yī)院2016年3月—2017年3月收治的冠心病心絞痛患者161例，隨機(jī)分為對(duì)照組（80例）和治療組（81例）。對(duì)照組患者口服替格瑞洛片，首劑量為2片，然后1片/次，2次/d。治療組患者在對(duì)照組基礎(chǔ)上靜脈滴注注射用益氣復(fù)脈（凍干），5.2 g加入5%的葡萄糖注射液500 mL，1次/d。兩組患者均治療2周。觀察兩組患者臨床療效，比較治療前后兩組患者心絞痛癥狀和評(píng)分、血小板聚集率（MPA）、血小板反應(yīng)指數(shù)（PRI）和不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組臨床總有效率為87.50%，顯著低于治療組的97.53%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間均顯著減少（P<0.05），西雅圖心絞痛評(píng)分顯著升高（P<0.05）；且治療組患者各指標(biāo)改善情況均明顯優(yōu)于對(duì)照組（P<0.05）。治療1周后，兩組患者的MPA均顯著降低、PRI均顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療1周和停藥12 h后，治療組患者M(jìn)PA和PRI較對(duì)照組改善更明顯（P<0.05）。治療后，對(duì)照組心血管不良事件發(fā)生率為10.00%，治療組為1.23%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療期間，對(duì)照組不良反應(yīng)發(fā)生率為13.75%，顯著高于治療組的2.47%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 注射用益氣復(fù)脈（凍干）聯(lián)合替格瑞洛治療冠心病心絞痛療效好、安全性高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy and safety of Yiqi Fumai (freeze-dried) for injection combined with ticagrelor in treatment of angina pectoris of coronary heart disease. Methods Patients (161 cases) with angina pectoris of coronary heart disease in the First People's Hospital of Shangqiu from March 2016 to March 2017 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Ticagrelor Tablets, the initial dose was 2 tablets, then 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Yiqi Fumai (freeze-dried) for injection on the basis of the control group, 5.2 g added into 5% Glucose Injection 500 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the angina pectoris symptoms and scores, MPA, PRI and the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.50%, which was significantly lower than 97.53% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P < 0.05), but SAQ scores were significantly increased (P < 0.05). And the improvement of these indexes in the treatment group after treatment was significantly better than that in the control group (P < 0.05). After treatment for 1 week, MPA in two groups was significantly decreased (P < 0.05), but PRI was significantly increased (P < 0.05). After treatment for 1 week and withdrawal for 12 h, MPA and PRI in the treatment group after treatment were significantly better than those in the control group (P < 0.05). After treatment, the incidence of adverse cardiovascular events in the control group was 10.00%, and the treatment group was 1.23%, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 13.75%, which was significantly higher than 2.47% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Yiqi Fumai for injection (freeze-dried) combined with ticagrelor has significant efficacy in treatment of angina pectoris of coronary heart disease with high safety, which has a certain clinical application value.